Vicentini M, et al. - Experts conducted an observational population-based study to evaluate the impact of metformin on cancer incidence in type 2 diabetes (T2DM), considering possible interactions with other glucose-lowering drugs and diabetes duration. In this study cohort, they involved diabetes patients aged 20–84 in December 2009, still alive and resident in Reggio Emilia province as of December 2011. They compared subjects taking metformin continuously with or without other hypoglycaemic drugs to subjects on diet-only therapy. No evidence of an antitumor effect of metformin was observed in this investigation. The data presented in this work showed a possible decrease only for breast, liver and prostate cancer, was compatible with random fluctuations.